About this paper
Should life science companies be expected to share patient-level data from their clinical trials? Groups such as the European Medicines Agency and the AllTrials campaign say yes; it's in the public interest to do so. Forward-thinking companies are taking bold steps toward data sharing because it's also good business and good science. This article summarizes discussion on the topic with industry leaders at the Clinical Trial Data Transparency Forum, sponsored by SAS, held in October 2013.